# OnCo record swog-s1418 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/swog-s1418/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "swog-s1418", "NCT02954874" ;
  schema:name "SWOG S1418 / NRG BR006"@en ;
  schema:alternateName "S1418"@en, "NRG-BR006"@en, "SWOG S1418"@en ;
  schema:description "SWOG S1418 is the trial that will say whether a year of pembrolizumab after surgery, on its own, helps women whose triple-negative breast cancer survived pre-operative chemotherapy. It finished recruiting 1,195 patients and is due to report from 2026."@en ;
  schema:url <https://onco.cc/trials/swog-s1418/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02954874> ;
  onco:status "active" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/swog/> ;
  onco:institutions <https://onco.cc/institutions/nci/> ;
  onco:terms <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/tnbc-residual-disease-decision/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/a-brave/>, <https://onco.cc/trials/impassion030/> .